Department of Gastroenterology

1. A Parallel Group Randomized open blinded end points evaluation, multicentric, dose escalation, phase-II study assessing the safety and efficacy of intra-arterial (hepatic) ex-vivo cultured adult allogenicmesenchymal stem cells in patients with alcoholic liver cirrhosis” (2012-2015)

2. Diabetes-Liver Disease Embrace: A cross-sectional multi-centric study to explore the effect of diabetes on short term outcome of acute and chronic liver disease(2016-till date)

3. A prospective, Multi- Centre, Double blind, Randomized Trial of Saroglitazar 4 mg versus Placebo in Patients with Non - Alcoholic Steatohepatitis (2016-2017)

4. A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 weeks in Subjects with Chronic Hepatitis C Virus (HCV) infection”.(2017-2018)

5. GS-VS-384-1943:- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

6. Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic

7. Steatohepatitis (NASH) and Bridging (F3) Fibrosis (2017)

1. Frequency of sleep abnormalities in patients with irritable bowel syndrome and its relationship with symptom severity, quality of life and effect of pharmacological intervention to improve sleep on these parameters PI

2. Indian IBS Consensus PI

3. Relationship between digestive symptoms and morbidity, mortality and fecal excretion of the virus among patients with Covid-19: A possible diagnostic role of fecal sample and potential for feco-oral transmission PI

4. A phase IIa, randomized double-blind, placebo-controlled factorial design, proof of concept trial to assess the safety, tolerability and efficacy of artesunate and curcumin in patients’s with Crohn’s disease, who continue to to have mild to moderate disease activity on an adequate dose of azathioprine PI

5. Multicentric, Phase IV, randomized, double blind, placebo controlled trial to assess effectiveness and safety of Lactobacillius acidophilus LA-5 and Bifidobacterium BB-12 in the treatment of Non-constipated IBS in adults aged 18 years to 65 years PI

6. Rome Foundation global epidemiological study on functional gastrointestinal disorder PI

7. Gastro-esophageal transport and reflux: A comprehensive analysis using an inter-disciplinary approach Co-PI

8. Lactose malabsorption in irritable bowel syndrome in the Tropics: Evaluation of diagnostic protocols and study of LPH and SERT genes potentially influencing development of symptoms following lactose ingestion PI

9. A multi-centric study on treatment of abdominal tuberculosis (intestinal or peritoneal): A randomized controlled trial to compare the 6 months of Cat I treatment with 9 months of Cat I Treatment (extension for 3 months) in abdominal tuberculosis under the Revised National Tuberculosis Control program PI from SGPGI

10. Evaluation of utility of pepsinogen-I, pepsinogen-II and gastrin-17 serum levels in diagnosis of cancer-associated gastric mucosal lesions like intestinal metaplasia (IM) in patients with and without H. pylori infection in India. PI

11. Gastro-esophageal Reflux Disease and Helicobacter pylori: Possible role of IL-1, IL-8 and Extra-cellular signal Regulated Kinases in gastric mucosal injury altering severity of the disease PI

12. Small intestinal bacterial overgrowth and small intestinal permeability in patients with irritable bowel syndrome in tropics: Role of interleukin-1 and its receptor antagonist and effect of eradication of bacterial overgrowth PI

13. Promotion of hygiene and sanitation in rural schools in U.P. and its impact on health: A pilot study Co-PI

14. Characterization of human Cryptosporidium infection in patients with immunocompromised states in northern India Co-PI

15. Pathogenesis of tropical sprue: Study of antroduodenal manometry, duodenal of transit time, fat induced ileal brake and small intestinal manometry PI

16. Pathogenesis of Helicobacter pylori associated gastroduodenal disease: Role of apoptosis and genetic polymorphism in bcl-2, c-myc and CASP-9 (an extension to project No. 2) PI

17. Prevalence of Helicobacter pylori infection and Cag A antibody status in patients with gastric carcinoma and controls: Possible mechanism of carcinogenesis involving apoptosis. PI

As Principal Investigator

1 Study the interferon induced genes as a biomarker of antiviral treatment outcome in chronic hepatitis C virus infection in North Indian population. __ ICMR __ 6y ( July 2011) Completed

2 Genetic risk factors and biomarkers of Non-alcoholic fatty liver disease __ ICMR __ Accepted

3 Diagnostic yield of endoscopic ultrasound–guided fine-needle aspiration of tubercular lymphadenitis using combination of cytology and Gene Xpert Mycobacterium tuberculosis/rifampicin (MTB/RIF) genes __ DM Project __ Completed

4 Diabetes-Liver disease embrace-Across sectional multi-centric study to explore the effect of Diabetes on short term outcome of acute and chronic liver disease. __ SGPGIMS, Lucknow __ 2 y (Sept,2014) Completed

5 Randomized, double blinded trial of role of Rifaximin in patients of chronic pancreatitis with small intestinal bacterial overgrowth __ SGPGIMS, Lucknow __ 2y ( Dec,2014) Completed

6 Endoscopic drainage of pancreatic pseudocysts at a tertiary care centre in northern India __ SGPGIMS, Lucknow __ 2y completed

7 To study & compare the frequency of SIBO in patients with alcoholic and idiopathic chronic pancreatitis __ SGPGIMS, Lucknow __ 2y (completed )

8 Micro-structural correlates of cognitive changes in chronic hepatitis C virus infection __ SGPGIMS __ 2011 (completed )

9 Role of Timed Barium Esophagogram in Achalasia Cardia __ SGPGIMS __ 2010 (completed )

10 A multicenter, randomized, open label, parallel-group phase IIB study on the efficacy and safety of oral regimens of DEB025 alone or in combination with ribavirin versus Standard of Care (peg-IFNα2a plus ribavirin) in treatment-naïve hepatitis C genotype 2 and 3 patients __ Novartis Pharmaceuticals, __ May 2011 (completed )

11 Virchow Biotech Pvt Ltd, Hyderabad funded clinical trial “Efficacy and safety of PEG-Interferon (peginterferon alpha-2b) for the treatment of chronic hepatitis C - An open-label study in India”. __ Virchow Biotech __ April 2011 to Dec 2012 (completed )

12 Incidence, risk factors &outcome of acute kidney injury in Acute Pancreatitis. __ SGPGI ,Intramural project __ 2 yrs. May 2010 (completed )

13 A Phase III, randomized, multi-centre, double-blind, parallel group, active comparator study to compare the efficacy and safety of SPD476 (mesalazine) 2.4g/day once daily (QD) with Asacol 1.6g/day twice daily (BID) in the maintenance of remission in patients with ulcerative colitis. __ Shire Pharmaceuticals, UK __ 2007-2009 (completed )

14 AI463-110: A comparative study of Chronic Hepatitis B subjects treated with Entecavir plus Tenofovir combination therapy Vs Entecavir monotherapy in adults who are treatment naïve to Nucleoside and Nucleotide: The BE-LOW Study. __ Bristol Myers Squibbs __ 2008-2011 (completed )

15 AI463-048- (Comparison of the Efficacy and Safety with Hepatitis B Virus and Evidence of Hepatic Decompensation)” __ Bristol Myers Squibbs __ 2008-2012 (completed )

16 AI463-111 - A Comparative Study of Entecavir vs Adefovir plus Lamivudine vs the Combination of Entecavir plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Subjects:The Define Study __ Bristol Myers Squibbs __ 2008- 2012 (completed )

17 Clinical trial “Protocol AI463 - 080 - Randomized, Observational Study to Assess Long-term Outcomes Associated with Nucleoside/Nucleotide Monotherapy for Patients with Chronic HBV Infection. __ Bristol Myer Squibb, USA (CRO: PPD) __ 10 Yrs 2008-2018 (completed )

As Co-Investigator

1 Interventional radiology in the management of iatrogenic bile duct injuries and benign biliary strictures. __ SGPGI __

2 Current utility ofTrans-gastric percutaneous drainage for the management of pancreatitis related retro gastric fluid collections. __ SGPGI __

3 Comparison of Performance Characteristics of Gastrolaryngeal Tube with the Standard Anesthetic Practice in patients undergoing Endoscopic Retrograde Cholangiopancreaticography“A Prospective Randomised Study” __ SGPGI __

4 Microbiological Characteristics of Tuberculous Peritonitis at a Tertiary Care Center in Northern India __ SGPGI __

5 Expression of PD-L1 in Ampullary Cancers and its Relation with MAP Kinase cascade __ SGPGI __

6 Evaluation of Pancreatic mass lesions by multidetector CT and endoscopic ultrasound __ SGPGI __ Sept,2014 (completed )

7 To study spectrum of morphological changes in the portal venous system and biliary system in patients with EHPVO and symptomatic PCC __ SGPGI __ Aug, 2013 (completed )

8 Effect of biliary drainage on liver elasticity in malignant biliary obstruction __ SGPGI __ July, 2013 (completed )

9 Evaluation of efficacy and safety of NCB-02 in Ulcerative Colitis __ Himalaya Drug Company, Bangalore, India __ Aug 2007- Oct 2009. (completed )

10 Evaluation of efficacy of HD-03/ES in virus B hepatitis (A phase III clinical trial __ Himalaya Drug Company, Bangalore, India __ Aug 2007- Oct 2009. (completed )

A systematic review to estimate the burden of HCV infection in WHO SEAR countries WHO SEAR office May 2020

Host determinants of Hepatitis E Disease Severity ICMR, India March 2019-Feb 2021

Hepatitis C virus genotype 3 variants associated with resistance to directly-acting anti-viral agents ICMR, India July 2019-June 2022

A systematic review to estimate the seroprevalence of HCV infection in India WHO India 2017 (Three months)

1. A double-blind randomized controlled trial of remosetron versus amitriptyline in patients with diarrhea-predominant irritable bowel syndrome and its relation with rectal hypersensitivity PI

2. Esophageal acidic reflux during nocturnal acid breakthrough in gastroesophageal reflux disease: Relationship with symptoms, lower esophageal sphincter pressure and body motility PI

3. Role of small bowel bacterial flora and GI transit time in tropical sprue. PI

1. Praveer Rai, Anjali Sharma, Ankur Gupta, Rakesh Agarwal: Frequency of SPINK1 N34S mutation in acute and recurrent acute pancreatitis. J Hepatobiliary Pancreat Sci. 2014 May 21. doi: 10.1002/jhbp.111

2. Rai Praveer, Kumar P, Mishra S, Aggarwal R.Low frequency of V617F mutation in JAK2 gene in Indian patients with hepatic venous outflow obstruction and extrahepatic portal venous obstruction.Indian J Gastroenterol. 2016 Sep;35(5):366-371